CCLA Investment Management lifted its stake in shares of NICE Ltd. (NASDAQ:NICE - Free Report) by 14.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 704,494 shares of the technology company's stock after purchasing an additional 87,003 shares during the quarter. NICE comprises about 1.9% of CCLA Investment Management's investment portfolio, making the stock its 26th largest position. CCLA Investment Management owned approximately 1.12% of NICE worth $119,517,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also made changes to their positions in NICE. Rhumbline Advisers boosted its position in shares of NICE by 8.7% in the 2nd quarter. Rhumbline Advisers now owns 3,358 shares of the technology company's stock worth $577,000 after buying an additional 269 shares in the last quarter. Choreo LLC purchased a new stake in shares of NICE in the 2nd quarter worth about $211,000. American Century Companies Inc. boosted its position in shares of NICE by 6.8% in the 2nd quarter. American Century Companies Inc. now owns 4,569 shares of the technology company's stock worth $786,000 after buying an additional 289 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of NICE by 12.8% in the 2nd quarter. Federated Hermes Inc. now owns 18,663 shares of the technology company's stock worth $3,209,000 after buying an additional 2,124 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in NICE by 12.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,056,537 shares of the technology company's stock valued at $181,693,000 after purchasing an additional 117,749 shares in the last quarter. 63.34% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
NICE has been the topic of a number of recent research reports. Northland Securities reduced their target price on shares of NICE from $275.00 to $250.00 and set an "outperform" rating on the stock in a report on Friday, November 15th. Piper Sandler restated a "neutral" rating on shares of NICE in a report on Thursday, November 14th. Royal Bank of Canada restated an "outperform" rating and issued a $260.00 target price on shares of NICE in a report on Friday, November 15th. Citigroup upped their target price on shares of NICE from $330.00 to $334.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Finally, Oppenheimer lowered shares of NICE from an "outperform" rating to a "market perform" rating in a report on Friday, November 15th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $259.50.
Read Our Latest Report on NICE
NICE Stock Performance
NICE traded down $2.20 on Wednesday, reaching $167.14. 412,078 shares of the company's stock were exchanged, compared to its average volume of 338,898. The company's 50 day moving average is $178.65 and its 200-day moving average is $174.43. The company has a market cap of $10.51 billion, a price-to-earnings ratio of 25.87, a PEG ratio of 1.46 and a beta of 1.06. NICE Ltd. has a twelve month low of $151.52 and a twelve month high of $270.73.
NICE Profile
(
Free Report)
NICE Ltd., together with its subsidiaries, provides cloud platforms for AI-driven digital business solutions worldwide. It offers CXone, a cloud native open platform; Enlighten, an AI engine for the customer engagement market; and smart self service enable organizations to address consumers' needs; and journey orchestration solutions that empower organizations to connect and route customers to deal with the customer's request, and connects them using real time AI-based routing.
Recommended Stories
Before you consider NICE, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NICE wasn't on the list.
While NICE currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.